Focused ultrasound relieves fibroid symptoms in women

May 29, 2007

OAK BROOK, Ill. -- A noninvasive ultrasound procedure effectively shrinks uterine fibroids and significantly relieves fibroid-related symptoms in women, according to the results of a multicenter clinical trial reported in the June issue of the journal Radiology. Magnetic resonance-guided, focused ultrasound surgery (MRgFUS) allows radiologists to precisely target fibroids without harming healthy surrounding tissue.

"This treatment immediately stops blood flow in the treated fibroid tissue, which results in a significant, sustained decrease in symptoms for up to 12 months," said the study's lead author, Fiona M. Fennessy, M.D., Ph.D., assistant professor of radiology at Harvard Medical School and staff radiologist at Brigham and Women's Hospital in Boston.

Uterine fibroids are benign growths of the muscle inside the uterus. According to the National Institutes of Health, at least 25 percent of women in the United States age 25 to 50 suffer from symptomatic uterine fibroids. Fibroid symptoms can include excessive menstrual bleeding, enlarged uterine size, frequent urination, pelvic pressure or pain and infertility.

According to the National Women's Health Information Center, fibroids are the primary reason for surgical removal of the uterus, accounting for approximately one-third of hysterectomies performed annually in the U.S. MRgFUS represents a noninvasive, outpatient alternative to hysterectomy.

"This treatment is ideal for older women who have completed their families and have a single or limited number of fibroids," said co-author Clare M. Tempany, M.D., professor of radiology at Harvard Medical School and director of Clinical Focused Ultrasound at Brigham and Women's Hospital.

The researchers studied 160 women with symptomatic fibroids. The women received pre-treatment MR imaging to identify and define the target fibroids. Radiologists then used MRgFUS to locate and treat the targeted fibroids while monitoring temperature changes in tissue.

Ninety-six patients were treated under the original study protocol (A), and 64 patients were treated under an optimized protocol (B). Protocol A allowed a maximum treatment time of 120 minutes and a maximum fibroid treatment volume of 100ccs (roughly six centimeters (cm) in diameter), or up to 33 percent of total fibroid volume. Protocol B allowed a maximum treatment time of 180 minutes and maximum fibroid treatment volume of 150ccs (about seven cm in diameter), or up to 33 percent of total volume in subserosal fibroids (those on the outer wall of the uterus) and 50 percent of volume in non-subserosal fibroids.

"Through this study, we've learned that MRgFUS can be optimized with newer protocols to have even better results than previously thought possible," Dr. Tempany said.

The findings showed significant symptom relief at three months and sustained relief at one year. Women treated with the optimized protocol reported greater symptom relief and quality of life improvement than those treated with the original protocol. No serious adverse effects were reported.

"We have shown that treating fibroids with an optimized, less restrictive protocol allows for treatment of a greater fibroid volume, which results in even greater symptomatic relief at clinical follow-up," Dr. Fennessy said.
-end-
Radiology is a monthly scientific journal devoted to clinical radiology and allied sciences. The journal is edited by Anthony V. Proto, M.D., School of Medicine, Virginia Commonwealth University, Richmond, Va. Radiology is owned and published by the Radiological Society of North America, Inc. (RSNA.org/radiologyjnl)

The Radiological Society of North America (RSNA) is an association of more than 40,000 radiologists, radiation oncologists, medical physicists and related scientists committed to excellence in patient care through education and research. The Society is based in Oak Brook, Ill. (RSNA.org)

"Uterine Leiomyomas: MR Imaging-guided Focused Ultrasound Surgery--Results of Different Treatment Protocols." Co-authoring the paper with Drs. Fennessy and Tempany are Nathan J. McDannold, Ph.D., Minna J. So, M.D., Gina K. Hesley, M.D., Bobbie Gostout, M.D., Hyun S. Kim, M.D., George A. Holland, M.D., Dennis A. Sarti, M.D., Kullervo Hynynen, Ph.D., Ferenc A. Jolesz, M.D., and Elizabeth A. Stewart, M.D.

Radiological Society of North America

Related Uterine Fibroids Articles from Brightsurf:

Artificial tissue used to research uterine contractions
Throughout an individual's lifetime, the uterus undergoes spontaneous contractions of the uterine wall, which can induce uterine peristalsis, a specific wavelike contraction pattern.

New targeted agent produces considerable responses in patients with uterine cancer
The DNA repair-blocking drug adavosertib shrinks tumors in nearly one-third of patients in clinical trial data to be shared at the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer.

Comparing effectiveness of 2 surgical methods for uterine prolapse
Uterine prolapse happens when weakened muscles and ligaments no longer provide enough support for the uterus, which then protrudes into or out of the vagina.

Uterine artery embolization can be considered for well controlled symptomatic leiomyomas
A new study published in the April 2019 issue of the American Journal of Roentgenology (AJR) investigates the safety of uterine artery embolization (UAE) for symptomatic leiomyomas in patients with various autoimmune diseases.

TGF-beta pathway protects against uterine cancer
Two new mouse models of uterine cancer reveal that the TGF-beta signaling pathway in uterine cells protects against the disease by suppressing the overgrowth and oncogenesis of the endometrium, the membrane lining the inside of the uterus.

Elagolix reduces menstrual bleeding from most common uterine tumors
A new oral drug significantly reduced menstrual bleeding for women with the most common gynecologic tumors in the United States - benign tumors that disproportionately affect African-Americans, an international clinical trial found.

Uterine cancer survivors are more likely to have cardiovascular problems
A new study in the Journal of the National Cancer Institute indicates that survivors of uterine cancer are more likely to experience cardiovascular problems years after treatment.

New drug combo improves survival of women with rare uterine cancer
Adding the monoclonal antibody drug trastuzumab -- already used to treat certain breast cancers -- to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value

A new tool for improving uterine transplant surgery
Future Science Group (FSG) today announced the publication of an article in Future Science OA demonstrating the first use of multispectral imaging in gynecology, in a uterine transplant setting.

Study shows increased risk of uterine fibroids in African-American women with a common form of hair
In a study of medical records gathered on hundreds of thousands of African-American women, Johns Hopkins researchers say they have evidence that women with a common form of hair loss have an increased chance of developing uterine leiomyomas, or fibroids

Read More: Uterine Fibroids News and Uterine Fibroids Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.